Papers/PMID:26700109
Effects of vitamin D2 or D3 supplementation on glycaemic control and cardiometabolic risk among people at risk of type 2 diabetes: results of a randomized double-blind placebo-controlled trial.
Diabetes, obesity & metabolism2016The record
3 findings · 1 compound · 3 endpoints · 1 null
What it reported
How to read these marksWhat moved
2 findings
vitamin D2 — decreases HDL cholesterol
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Finding“In the D2 group there were small, but statistically significant, decreases from baseline relative to placebo in total cholesterol and ApoB (favouring D2), as well as in HDL cholesterol and ApoA1 (favouring placebo; Figure 4A).”
Quoted verbatim from Effects of vitamin D2 or D3 supplementation on glycaemic control and cardiometabolic risk among people at risk of type 2 diabetes: results of a randomized double-blind placebo-controlled trial.. - Study
- RCT
- Duration
- 4 months
- Dose
- 100,000 IU ergocalciferol (vitamin D2) orally once monthly for 4 months
- Population
- Adults aged 30-75 at elevated risk of type 2 diabetes (non-diabetic hyperglycaemia or positive diabetes risk score), UK; vitamin D2 arm versus placebo arm
Effects of vitamin D2 or D3 supplementation on glycaemic control and cardiometabolic risk among people at risk of type 2 diabetes: results of a randomized double-blind placebo-controlled trial.2016PMID:26700109Industry fundedPermalink
vitamin D2 — decreases total cholesterol (TC)
LimitedEvidence strength: limited. Human evidence with several recorded weaknesses, or a design that tops out at limited.Finding“In the D2 group there were small, but statistically significant, decreases from baseline relative to placebo in total cholesterol and ApoB (favouring D2), as well as in HDL cholesterol and ApoA1 (favouring placebo; Figure 4A).”
Quoted verbatim from Effects of vitamin D2 or D3 supplementation on glycaemic control and cardiometabolic risk among people at risk of type 2 diabetes: results of a randomized double-blind placebo-controlled trial.. - Study
- RCT
- Duration
- 4 months
- Dose
- 100,000 IU ergocalciferol (vitamin D2) orally once monthly for 4 months
- Population
- Adults aged 30-75 at elevated risk of type 2 diabetes (non-diabetic hyperglycaemia or positive diabetes risk score), UK; vitamin D2 arm versus placebo arm
Effects of vitamin D2 or D3 supplementation on glycaemic control and cardiometabolic risk among people at risk of type 2 diabetes: results of a randomized double-blind placebo-controlled trial.2016PMID:26700109Industry fundedPermalink
What did not
1 finding
vitamin D2 — no detected effect on C-reactive protein concentration
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull result“Among the secondary outcomes, there were no differences comparing D2 with placebo or D3 with placebo for anthropometric measures, blood pressure, hsCRP, CVD risk, assessed by UKPDS risk engine, hepatic markers, or fructosamine.”
Quoted verbatim from Effects of vitamin D2 or D3 supplementation on glycaemic control and cardiometabolic risk among people at risk of type 2 diabetes: results of a randomized double-blind placebo-controlled trial.. - Study
- RCT
- Duration
- 4 months
- Dose
- 100,000 IU ergocalciferol (vitamin D2) orally once monthly for 4 months
- Population
- Adults aged 30-75 at elevated risk of type 2 diabetes (non-diabetic hyperglycaemia or positive diabetes risk score), UK; vitamin D2 arm versus placebo arm
Effects of vitamin D2 or D3 supplementation on glycaemic control and cardiometabolic risk among people at risk of type 2 diabetes: results of a randomized double-blind placebo-controlled trial.2016PMID:26700109Industry fundedPermalink